about
Cellular adhesome screen identifies critical modulators of focal adhesion dynamics, cellular traction forces and cell migration behaviour.Identification of cisplatin-regulated metabolic pathways in pluripotent stem cellsp140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation.Diclofenac inhibits tumor necrosis factor-α-induced nuclear factor-κB activation causing synergistic hepatocyte apoptosis.Systems microscopy approaches to understand cancer cell migration and metastasis.RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signalingBinding of soluble fibronectin to integrin alpha5 beta1 - link to focal adhesion redistribution and contractile shape.The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest.Integrins in regulation of tissue development and function.Concise review: workshop review: understanding and assessing the risks of stem cell-based therapiesIntegrins: regulators of tissue function and cancer progression.No preclinical rationale for IGF1R directed therapy in chondrosarcoma of boneIntegrins control motile strategy through a Rho-cofilin pathway.Integrin switching modulates adhesion dynamics and cell migrationThe cancer stem cell microenvironment and anti-cancer therapy.Targeted radiosensitization in prostate cancer.Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.A guide to mechanobiology: Where biology and physics meet.Deciphering Epithelial-Mesenchymal Transition Regulatory Networks in Cancer through Computational ApproachesInhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.SYK is a candidate kinase target for the treatment of advanced prostate cancer.β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer.Combining doublecortin-like kinase silencing and vinca alkaloids results in a synergistic apoptotic effect in neuroblastoma cells.Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens.Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells.The regulation of MacMARCKS expression by integrin beta3.Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma.Properties of metastasizing and nonmetastasizing human melanoma cells.Establishment and characterization of an uveal-melanoma cell line.Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis.Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma.Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.Ignoring matrix boundaries when the LKB1 master kinase is gone.Adverse outcome pathways: opportunities, limitations and open questionsTargeting survivin as a potential new treatment for chondrosarcoma of bone.Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity.MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
P50
Q27316544-53F142E5-C806-412E-B707-F60012C78042Q28534469-2998C3B0-D27D-44CB-8E46-C8645BFB646DQ30010279-48D60767-3333-4873-8DDE-B996A9B1A7E0Q33854289-B1E4D92B-019B-416F-BFD9-C0D2CD8E450FQ34106013-D669ABD4-A8F2-4EA8-AB76-63C18A66BFA7Q34401105-C5BACA6C-59C9-4C3A-B3A9-1BDB99E7403FQ34793769-8FA4C37B-05C9-4E9F-9969-3248D8757329Q35165148-232DEB92-D914-4E6D-99B3-B2AAB05C395FQ35170439-77D7263C-A2F4-401D-8CA8-4693E02AF869Q35200156-139298BC-36CA-43EB-8FDB-DCEEF687F790Q36074575-DD946366-64BC-43B5-A76F-633E4DFA0581Q36078319-5C090B09-6416-4663-87D0-B4B085BF699AQ36321708-2767FB93-C8DE-41D9-B3E2-1FCB178CC35FQ37415256-8D538D9A-F016-490C-BC90-D302410A3AFEQ37628729-BFDFA8AF-C2F9-4FC6-9AC1-C16FD8DCA8C6Q38085382-090B8B32-51D2-4546-839F-F7FAD25807E5Q38262894-94DFBB63-007D-4494-A1A7-15A315DF0EC2Q38495688-83CB6AC2-2B96-4890-8968-E5820BE1B3E5Q38616552-11E1ECE6-BCAC-4EEF-A90D-9D6971C2CD62Q38884358-50F27EBC-AD35-4231-B44E-1BD04B9583A9Q38901610-39D6B934-964D-4422-83D9-2A1AA73D22CDQ38941178-B342C46B-2263-4DF7-A53A-F29334B2A6AAQ39024860-DB61C6C3-D302-47E1-BA88-76BBB166B1FCQ39366880-00AA0283-705F-4A30-ABA5-0EAC5BCA9E49Q39454727-1EEA2C06-A55F-4D6E-B2B0-DFB7A6297ABFQ39727910-F793CC32-4634-4F20-B4F9-204646651860Q40172566-1AF91BAA-196F-44B4-BC01-B676C03E4AF1Q40410467-E8D803B1-FA05-40FB-AB50-DCF4702BDA50Q40435595-3D15230E-6DF9-46CC-B661-4FD8D673CCDCQ40978454-6B8633AB-B42F-4EE5-B134-5219A068971CQ41168924-B2C1CD18-57C6-4050-9ED0-C5DBAA424178Q41233558-F5E3F96F-BAF7-4C55-A1CD-5C92E9C9285EQ41716525-97647D51-563A-452B-906F-4D0CA70290B4Q41912916-DDF189FE-9EC2-4B19-AA9A-B3EAAF43D31FQ42307037-5FF75F7C-C503-479B-9731-3A92428FF7A0Q42419178-8E508E2C-AF99-4C34-ACE2-CDEDA4292643Q42705921-C64B5407-34F1-4347-95C1-162996580B2DQ42748194-140DBF74-BFCC-4DBB-9B0A-2FBB407BB890Q47707892-83960DD6-B231-4C32-ABF8-7C290B86C656Q48674744-99AA0A01-48E9-40B2-B717-7806AC5B462F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Erik Danen
@ast
Erik Danen
@en
Erik Danen
@es
Erik Danen
@nl
type
label
Erik Danen
@ast
Erik Danen
@en
Erik Danen
@es
Erik Danen
@nl
altLabel
E. Danen
@nl
prefLabel
Erik Danen
@ast
Erik Danen
@en
Erik Danen
@es
Erik Danen
@nl
P106
P21
P31
P496
0000-0002-0491-6345
P735
P7449
PRS1272152